Shots: Voyager retains full rights to the vectorization technology and novel vectorized Abs emerges from the collaboration and has the right to pursue vectorized Ab programs targeting tau and alpha-synuclein alone or in collaboration with another partner As per collaboration agreements, Voyager has received an upfront payment to perform research and preclinical development of vectorized […]Read More
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a […]Read More
Shots: Voyager to receive $165M upfront including $115M in cash, $50M equity investment at $11.96/share and $1.7B milestones for its four gene therapy programs including VY-AADC & VY-FXN01. Additionally, Neurocrine to fund the two undisclosed gene therapy programs and Voyager to receive milestone and royalties on its WW sales Neurocrine to fund P-II/III & P-I […]Read More
Shots: Voyager’s program for Huntington’s Disease and Amyotrophic Lateral Sclerosis assessing VY-HTT01 at five wks. post-dosing in adult non-human primates & VY-SOD102 one-time intraparenchymal infusion after laminectomy The program demonstrated reduction in HTT mRNA by 68% in the caudate, 67% in the putamen, 73% in the thalamus, and 32% in cortical neurons & reduction in […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
